000095789 001__ 95789
000095789 005__ 20230519145346.0
000095789 0247_ $$2doi$$a10.1016/j.transproceed.2020.08.029
000095789 0248_ $$2sideral$$a120252
000095789 037__ $$aART-2021-120252
000095789 041__ $$aeng
000095789 100__ $$0(orcid)0000-0001-5134-1006$$aBenito, R.$$uUniversidad de Zaragoza
000095789 245__ $$aClinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation
000095789 260__ $$c2021
000095789 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095789 5203_ $$aBackground: Frequent and rapid development of myelopathy has been reported in individuals with human T-lymphotropic virus type 1 (HTLV-1) infection following solid organ transplantation. There is no information regarding HTLV-2, a closely related virus that often infects injection drug users.
Methods: This study includes a retrospective analysis of all consecutive organ transplants performed during the last 2 decades at a large reference transplantation unit in Spain. All participants were tested for anti-HTLV antibodies.
Results: A total of 2019 individuals were tested for HTLV during the study period, including 663 potential donors and 1356 recipient candidates. Twelve (0.59%) were reactive on initial HTLV serologic screening, but only 6 (all recipients) were confirmed as positive, all for HTLV-2. Two recipients underwent liver transplantation and have remained asymptomatic despite being on tacrolimus for 4 and 8 years, respectively. Likewise, the remaining 4 HTLV-2 carriers have not developed clinical complications potentially associated with HTLV-2.
Conclusions: Unlike HTLV-1 infection, HTLV-2 infection in the transplantation setting does not seem to be associated with rapid development of neurologic complications, Given the cross-seroreactivity between HTLV-1 and HTLV-2, discriminatory rapid tests are urgently needed and would reduce unnecessary organ discharge.
000095789 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000095789 590__ $$a1.014$$b2021
000095789 591__ $$aIMMUNOLOGY$$b159 / 163 = 0.975$$c2021$$dQ4$$eT3
000095789 591__ $$aTRANSPLANTATION$$b24 / 26 = 0.923$$c2021$$dQ4$$eT3
000095789 591__ $$aSURGERY$$b191 / 214 = 0.893$$c2021$$dQ4$$eT3
000095789 594__ $$a1.7$$b2021
000095789 592__ $$a0.286$$b2021
000095789 593__ $$aTransplantation$$c2021$$dQ3
000095789 593__ $$aSurgery$$c2021$$dQ3
000095789 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095789 700__ $$0(orcid)0000-0002-2037-3213$$aGil, J.
000095789 700__ $$aSahagún, J.$$uUniversidad de Zaragoza
000095789 700__ $$aSoriano, V.
000095789 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000095789 773__ $$g53, 2 (2021), 743-745$$pTransplant. proc.$$tTransplantation Proceedings$$x0041-1345
000095789 8564_ $$s200283$$uhttps://zaguan.unizar.es/record/95789/files/texto_completo.pdf$$yVersión publicada
000095789 8564_ $$s30773$$uhttps://zaguan.unizar.es/record/95789/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095789 909CO $$ooai:zaguan.unizar.es:95789$$particulos$$pdriver
000095789 951__ $$a2023-05-18-13:20:56
000095789 980__ $$aARTICLE